2. Search Result
Search Result
Results for "

BRD9 bromodomain

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18975
    I-BRD9
    Maximum Cited Publications
    9 Publications Verification

    		 Epigenetic Reader Domain Inflammation/Immunology Cancer
    I-BRD9 is a selective cellular chemical probe of bromodomain-containing protein 9 (BRD9) with pIC50 value of 7.3 μM. I-BRD9 has high selectivity for bromodomain and extra terminal domain (BET) family and highly homologous bromodomain-containing protein 7 (BRD7). I-BRD9 can be used to identify genes regulated by BRD9 in Kasumi-1 cells involved in oncology and immune response pathways .
    I-BRD9
  • HY-153367
    FHD-609
    2 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    FHD-609 is a PROTAC degrader and inhibitor of BRD9 (Bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment. (Blue: BRD9 ligand-6 (HY-49393), Black: linker (HY-168309); Pink: (S)-Deoxy-thalidomide-Br (HY-168308) ) .
    FHD-609
  • HY-100352
    BI-9564
    2 Publications Verification

    		 Epigenetic Reader Domain Cancer
    BI-9564, a chemical probe, is a potent, selective and cell-permeable BRD9/BRD7 bromodomains inhibitor, with IC50s of 75 nM and 3.4 μM and Kds of 14 nM and 239 nM, respectively. BI-9564 has an IC50 of > 100 μM for BET family .
    BI-9564
  • HY-107477
    GSK8573

    		Epigenetic Reader Domain Cancer
    GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .
    GSK8573
  • HY-148739
    dBRD 9-A

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma .
    dBRD 9-A
  • HY-19553
    LP99

    		Epigenetic Reader Domain Inflammation/Immunology
    LP99, an epigenetic probe, is a potent and selective inhibitor of the BRD7 and BRD9 bromodomains with a Kd of 99 nM against BRD9. LP99 disrupts the binding of BRD7 and BRD9 to chromatin in cells .
    LP99
  • HY-100517
    TP-472
    2 Publications Verification

    		 Epigenetic Reader Domain Apoptosis Cancer
    TP-472, a chemical probe, is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7 . TP-472 induces apoptosis of melanoma cells .
    TP-472
  • HY-156744
    DBr-1

    		PROTACs Epigenetic Reader Domain Cancer
    DBr-1 is a potent BRD9 PROTAC degrader (KD: 13 nM). DBr-1 can overcome intrinsic resistance to VHL-degrader. Blue: DCAF1 binder (HY-149934), Black: linker, Pink: BRD9/BRD7 bromodomains inhibitor (HY-100352) .
    DBr-1
  • HY-148116
    DN02

    		Epigenetic Reader Domain Cancer
    DN02 is a potent, selective BRD8 bromodomain probe. DN02 has exhibits high affinity for the BRD8 (1) (Ki=32 nM), which is 30-fold more affinity than BRD8 (2) (Ki>1000 nM) .
    DN02
  • HY-149420
    BRD7-IN-2

    		Epigenetic Reader Domain Others
    BRD7-IN-2 (compound 2-77) is a potent inhibitor of bromodomain-containing protein 7 (BRD7), targeting to prostate cancer cells. BRD7-IN-2 is selective for BRD7 rather than BRD9, with IC50s of 5.4 μM, and >300 μM, respectively.
    BRD7-IN-2
  • HY-117865
    GNE-886

    		Epigenetic Reader Domain Cancer
    GNE-886 (Compound 21) is a potent and selective inhibitor of Cat eye syndrome chromosome region candidate 2 bromodomain (CECR2) (BRD) with an IC50 value of 0.016 µM and an EC50 value of 370 nM. GNE-886 also inhibits BRD9 with an IC50 value of 1.6 µM .
    GNE-886
  • HY-178043
    BTR2038

    		Epigenetic Reader Domain Others
    BTR2038 is a BRD9 degrader. BTR2038 consistis of a BRD9 bromodomain ligand (Bl-7273 analoag), a linker and BTR2000 (HY-172563). BTR2038 induces targeted degradation of V5-tagged human BRD9. BTR2038 can be used for the study of biological processes and diseases associated with abnormal BRD9 protein function .
    BTR2038
  • HY-149421
    BRD7-IN-3

    		Epigenetic Reader Domain Cancer
    BRD7-IN-3 (compound 1-78) is a dual inhibitor of bromodomain-containing proteins BRD7/BRD9 with IC50s of 1.6 μM and 2.7 μM respectively .
    BRD7-IN-3
  • HY-100517R
    TP-472 (Standard)

    		Epigenetic Reader Domain Reference Standards Apoptosis Cancer
    TP-472 (Standard) is the analytical standard of TP-472 (HY-100517). This product is intended for research and analytical applications. TP-472, a chemical probe, is a selective BRD9/7 inhibitor, with Kds of 33 nM and 340 nM for BRD9 and BRD7, respectively. TP-472 exhibits >30-fold selectivity for BRD9 over other bromodomain family members except BRD7 . TP-472 induces apoptosis of melanoma cells .
    TP-472 (Standard)
  • HY-149806
    Bromodomain IN-2

    		Epigenetic Reader Domain Cancer
    BD-IN-1 is a pan bromodomain (BD) inhibitor with KD values of 250, 420, 130, 430, 67, 240, 970 nM for BRD4(1), CBP, BRPF1B, BRD7, BRD9, BRDT(1), CECR2 respectively. BD-IN-1 shows antiproliferative activity .
    Bromodomain IN-2
  • HY-100352R
    BI-9564 (Standard)

    		Epigenetic Reader Domain Reference Standards Cancer
    BI-9564 (Standard) is the analytical standard of BI-9564 (HY-100352). This product is intended for research and analytical applications. BI-9564, a chemical probe, is a potent, selective and cell-permeable BRD9/BRD7 bromodomains inhibitor, with IC50s of 75 nM and 3.4 μM and Kds of 14 nM and 239 nM, respectively. BI-9564 has an IC50 of > 100 μM for BET family .
    BI-9564 (Standard)
  • HY-107477R
    GSK8573 (Standard)

    		Reference Standards Epigenetic Reader Domain Cancer
    GSK8573 (Standard) is the analytical standard of GSK8573 (HY-107477). This product is intended for research and analytical applications. GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .
    GSK8573 (Standard)
  • HY-180886
    ZD-1-186

    		Molecular Glues c-Myc Cancer
    ZD-1-186 is a nondegradative molecular glue that potently suppresses MYC and robustly induces CDKN1A (p21) in diffuse large B-cell lymphoma cells. ZD-1-186 brings together BCL6 with BRD9, a noncanonical BAF complex bromodomain protein implicated in maintaining MYC transcriptional output in specific lymphoma contexts. ZD-1-186 can be used for targeted transcriptional rewiring research .
    ZD-1-186
  • HY-182766
    AMX-883

    		Molecular Glues Epigenetic Reader Domain Cancer
    AMX-883 a selective and orally active BRD9 molecular glue degrader that drives differentiation in acute myeloid leukaemia. AMX-883 shows selectivity over all other bromodomain containing proteins and proteome wide. AMX-883 does not employ the commonly used E3 ligases (cereblon, VHL) but instead drives degradation via DCAF16 as a targeted glue. AMX-883 can be used for the study of acute myeloid leukaemia (AML) .
    AMX-883
  • HY-107446
    BI-7273 acid

    		Ligands for Target Protein for PROTAC Epigenetic Reader Domain Others
    BI-7273 acid, BI-7273 (HY-100351) derivative, is a BRD9 PROTAC ligand. BI-7273 acid can be conjugated with E3 ligase Ligand Thalidomide (HY-14658) and linker to synthesize BRD9 PROTAC degrader dBRD 9-A (HY-148739) .
    BI-7273 acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: